Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

NCT04006288 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: Clopidogrel
DRUG: Prasugrel
DRUG: ticagrelor
DRUG: aspirin
DRUG: rivaroxaban

Sponsor

University of Florida

Collaborators

[object Object]